Affidea works in partnership with ScreenPoint Medical to develop the diagnostic accuracy of screening mammography used from the IA

Amsterdam, 5 September 2016 / PRNewswire / – Affidea and ScreenPoint Medical announced a strategic partnership to streamline and improve the clinical performance of mammography screening and advance the early detection of breast cancer. This partnership will support Affidea's growing presence in the European breast imaging market and provide ScreenPoint Medical with a unique opportunity to launch the innovative Transpara (TM) AI solution in three other European countries. – Greece, Hungary and Spain.

Transpara (TM) is a breast cancer screening solution for AI that uses in-depth learning algorithms to automatically detect lesions suspected of causing breast cancer in 2D and 3D mammograms. The software classifies mammograms on a 10-point scale indicating the risk of cancer. Transpara (TM) Score can be used to pre-screen reviews and prioritize patients requiring further investigation. Radiologists have CAD markers for calcifications, soft tissue injuries and interactive decision support so they can interpret images with greater accuracy. Studies have shown that Transpara (TM) matches the performance of radiologists[1] and act as a second opinion to increase the reliability and accuracy of diagnosis[2],

Giuseppe Recchi, CEO of Affidea, said: "This is our second innovative artificial intelligence project integrated into our European network, with the goal of extending precision medicine, improving accuracy and enabling more diagnostics." Personalized and More Personalized Breast Care Using Advanced AI Solutions Our physicians are taking full advantage of the AI ​​tools that enable them to further secure the diagnosis and ultimately save more lives. We look forward to implementing this AI for the benefit of women across Europe and working with our partners to: develop the best clinical solutions for patients and physicians. "

Teacher. Nico Karssemeijer, CEO of ScreenPoint Medical, added: "We are excited about this strategic partnership, in which ScreenPoint will have a unique opportunity to work with the largest provider of advanced diagnostic imaging in Europe to introduce AI into the practice of breast imaging." , sharing with Affidea the vision that innovative AI solutions are needed to help radiologists meet the growing demands for quality and efficiency as diagnostic imaging becomes more complex We are proud to say that Transpara (TM) is one of the first artificial intelligence applications implemented by Affidea, and we look forward to working together. "

Rowland Illing, Senior Vice President, Head of Affidea's Medical & Digital Strategy, added: "We are pushing the boundaries of increased diagnostic accuracy, better personalized and improved clinical outcomes, and an exceptional patient experience." The new AI solution, Transpara(TM) It will provide our physicians with automated clinical decision support to improve reading performance, differentiate healthy tissue faster from tumor tissue, and increase the accuracy of diagnosis. "

Transpara (TM) is FDA approved and CE marked for use with digital mammography and digital breast tomosynthesis.

Facts about breast cancer:

  • Breast cancer is the most common cancer in women, with an estimated frequency of 560,000 cases in 2018 in Europe.[3]
  • One of the 8 women in the EU-28 is suffering from breast cancer.[4]
  • According to the World Health Organization, 627,000 women died of breast cancer in 2018 worldwide.[3] of which 150,000[4] in Europe.

1 "Autonomous Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison with 101 Radiologists (Independent Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison with 101 Radiologists)", Rodriguez-Ruiz et al., JNCI: Journal de National Cancer Institute, djy222,, 2019.

2 "Breast cancer detection by mammography: effect of the artificial intelligence support system": Rodríguez-Ruiz et al., Radiology 290: 2, 305-314, 2019.

3 World Cancer Observatory: Cancer Today (World Cancer Observatory: Cancer Today). LYON, France: International Agency for Research on Cancer,

Curado MP et al. Cancer Incidence Across Five Continents, Volume IX, IARC Scientific Publications No. 160. IARC Press: Lyon: 2007.

Logo –

Surveys and contact:

Oana Dumitroiu
Responsible for the brand and the communication of the affidés
+ 40-738-674-320